Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...
The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results